Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Santomasso, Bianca Denise

Sloan-Kettering Inst Can Research
United States

Comprehensive Molecular and Clinical Characterization of Acute and Chronic Neurotoxicity Following CAR-T Cell Therapy 5R01CA293922-02 Monica Epstein, B.S.N., RN, OCN
Santomasso, Bianca Denise

Sloan-Kettering Inst Can Research
United States

Comprehensive Molecular and Clinical Characterization of Acute and Chronic Neurotoxicity Following CAR-T Cell Therapy 5R01CA293922-02 Monica Epstein, B.S.N., RN, OCN
Santos-Reyes, Luis Javier

Comprehensive Cancer Center/ Univ/Pr
United States

Puerto Rico NCI Community Oncology Research Program (Puerto Rico NCORP) 3UG1CA189862-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Santos-Reyes, Luis Javier

Comprehensive Cancer Center/ Univ/Pr
United States

Puerto Rico NCI Community Oncology Research Program (Puerto Rico NCORP) 3UG1CA189862-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Saphner, Thomas J

Aurora Health Care, Inc.
United States

Aurora NCORP Community Site 3UG1CA190140-11S1 Vanessa A. White, M.P.H.
Saphner, Thomas J

Aurora Health Care, Inc.
United States

Aurora NCORP Community Site 3UG1CA190140-11S1 Vanessa A. White, M.P.H.
Schallenkamp, John M.

Montana Cancer Consortium
United States

Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and Wyoming 3UG1CA189872-11S1 Vanessa A. White, M.P.H.
Schallenkamp, John M.

Montana Cancer Consortium
United States

Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and Wyoming 3UG1CA189872-11S1 Vanessa A. White, M.P.H.
Schaverien, Mark V

University Of Tx Md Anderson Can Ctr
United States

Lymphedema Prevention Through Immediate Lymphatic Reconstruction 5R01CA292908-02 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Schaverien, Mark V

University Of Tx Md Anderson Can Ctr
United States

Lymphedema Prevention Through Immediate Lymphatic Reconstruction 5R01CA292908-02 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Schedin, Pepper J

Oregon Health & Science University
United States

NSAIDs During Postpartum Involution for Breast Cancer Chemoprevention 5R01CA169175-11 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Schenker, Yael

University Of Pittsburgh At Pittsburgh
United States

Patient-centered and efficacious advance care planning in cancer: the PEACe comparative effectiveness trial 5R01CA235730-06 Brennan Streck, Ph.D., RN, M.P.H.
Schmidt, Christian Maximillian

Indiana University Indianapolis
United States

Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer 5U01CA239522-05 Claire Zhu, Ph.D.
Schmit, Stephanie L.

Cleveland Clinic Lerner Com-Cwru
United States

Variation in tumor-associated immune profiles and colorectal cancer outcomes 5R01CA248931-05 Asad Umar, D.V.M., Ph.D.
Schoen, Robert E.

University Of Pittsburgh At Pittsburgh
United States

Blood-Based Testing for Advanced Adenoma 5U01CA271884-04 Matthew Young, Ph.D.